Erlotinib Hydrochloride for Treat Non-Small Cell Lung Cancer 183319-69-9

Model NO.: Erlotinib Hydrochloride
Service: Resend Policy
Wickr: Steroidsteroid
Standard: ISO
Delivery Time: Within 2 Hours
Usages: Pharmaceutical Intermediates
Purity: 99%
MOQ: 50ml
Suitable for: Elderly, Children, Adult
State: Liquid
Trademark Is: Jyy
Trademark: Pharma
Transport Package: Camouflage Packaging
Specification: Camouflage packaging
Origin: Wuhan
Model NO.: Erlotinib Hydrochloride
Service: Resend Policy
Wickr: Steroidsteroid
Standard: ISO
Delivery Time: Within 2 Hours
Usages: Pharmaceutical Intermediates
Purity: 99%
MOQ: 50ml
Suitable for: Elderly, Children, Adult
State: Liquid
Trademark Is: Jyy
Trademark: Pharma
Transport Package: Camouflage Packaging
Specification: Camouflage packaging
Origin: Wuhan


Erlotinib Hydrochloride for Treat Non-Small Cell Lung Cancer 183319-69-9

Product Name: Erlotinib hydrochloride
Synonyms: ERLOTINIB HCL;ERLOTINIB HCL SALT;ERLOTINIB HCL SALT :TARCEVA;Erlotinib, Hydrochloride Salt;N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, Hydrochloride Salt, OSI 774, Tarceva; N-(3-Ethynylphenyl)-6,7-bis-(2-methoxyethoxy)-quinazolin-4-amine;[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4yl]-(3-ethynyl-phenyl)-amine;Tarceva Hydrochloride See E625000
CAS: 183319-69-9
MF: C22H24ClN3O4
MW: 429.9



Erlotinib hydrochloride Overview

Erlotinib hydrochloride is hydrochloride of molecular targeted drug erlotinib. The US Food and Drug Administration (FDA) has approved erlotinib (Tarceva) in combination with gemcitabine for the first-line treatment of locally advanced and metastatic pancreatic cancer.
Small molecule compound erlotinib is a kind of receptor tyrosine kinase inhibitors. It can inhibit the phosphorylation reaction through competitively combined with the catalytic site of receptor tyrosine kinase tyrosine with the ATP, thus blocking the under proliferative signal transduction, and inhibiting the activity of tumor cell ligand-dependent HER-1/EGFR in order to inhibit tumor cell proliferation. Erlotinib is another tyrosine kinase inhibitor for treatment of NSCLC. The results of clinical trials showed that its main toxicity and side effect were dose-dependent skin rashes and diarrhea, other rare side effects were headache, nausea, vomiting and the like.

Erlotinib Hydrochloride for Treat Non-Small Cell Lung Cancer 183319-69-9




Our advantange

Packing
Professional packing with professional materials, and We'll give clients several Packing way to choose after you contact me through my email

Quality
Our company is a professional leading factory in China in pharmaceutical area, ach batch of steroid powders have to tested by our QC(quality control) department before they are allowed to sell.

Delivery
We can pack your powders within 48 hours after your payment, and corresponding picture of your powders' parcel will be sent to you.

Price
Best prices you're sure to be satisfied, the more you buy, the more competitive prices you get.

Payment
T/T in advance, WU or Money Gram

Erlotinib Hydrochloride for Treat Non-Small Cell Lung Cancer 183319-69-9


Erlotinib Hydrochloride for Treat Non-Small Cell Lung Cancer 183319-69-9

Product Name: Erlotinib hydrochloride
Synonyms: ERLOTINIB HCL;ERLOTINIB HCL SALT;ERLOTINIB HCL SALT :TARCEVA;Erlotinib, Hydrochloride Salt;N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, Hydrochloride Salt, OSI 774, Tarceva; N-(3-Ethynylphenyl)-6,7-bis-(2-methoxyethoxy)-quinazolin-4-amine;[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4yl]-(3-ethynyl-phenyl)-amine;Tarceva Hydrochloride See E625000
CAS: 183319-69-9
MF: C22H24ClN3O4
MW: 429.9



Erlotinib hydrochloride Overview

Erlotinib hydrochloride is hydrochloride of molecular targeted drug erlotinib. The US Food and Drug Administration (FDA) has approved erlotinib (Tarceva) in combination with gemcitabine for the first-line treatment of locally advanced and metastatic pancreatic cancer.
Small molecule compound erlotinib is a kind of receptor tyrosine kinase inhibitors. It can inhibit the phosphorylation reaction through competitively combined with the catalytic site of receptor tyrosine kinase tyrosine with the ATP, thus blocking the under proliferative signal transduction, and inhibiting the activity of tumor cell ligand-dependent HER-1/EGFR in order to inhibit tumor cell proliferation. Erlotinib is another tyrosine kinase inhibitor for treatment of NSCLC. The results of clinical trials showed that its main toxicity and side effect were dose-dependent skin rashes and diarrhea, other rare side effects were headache, nausea, vomiting and the like.

Erlotinib Hydrochloride for Treat Non-Small Cell Lung Cancer 183319-69-9




Our advantange

Packing
Professional packing with professional materials, and We'll give clients several Packing way to choose after you contact me through my email

Quality
Our company is a professional leading factory in China in pharmaceutical area, ach batch of steroid powders have to tested by our QC(quality control) department before they are allowed to sell.

Delivery
We can pack your powders within 48 hours after your payment, and corresponding picture of your powders' parcel will be sent to you.

Price
Best prices you're sure to be satisfied, the more you buy, the more competitive prices you get.

Payment
T/T in advance, WU or Money Gram

Erlotinib Hydrochloride for Treat Non-Small Cell Lung Cancer 183319-69-9

ICU Bed

ICU Bed,Hospital Equipment ,Hospital Jobs ,Hospital Bedroom

Prefabricated Building Co., Ltd. , http://www.nbhospitalsupplies.com